VALENCIA, Calif., Jan. 27, 2017 -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) will host a conference call to discuss Company developments at 5:00 PM (Eastern Time) on February 1, 2017.
Presenting from the Company will be its Chief Executive Officer, Matthew Pfeffer and Chief Commercial Officer, Michael Castagna.
To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the participant passcode: 44112877. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com under News & Events.
A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 4411 2877#. A replay will also be available on MannKind's website for 14 days.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Company Contact: Rose Alinaya SVP, Finance 661-775-5300 [email protected]


Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Italy Fines Apple €98.6 Million Over App Store Dominance
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 



